Key points are not available for this paper at this time.
Specific patient populations are often excluded from oncology trials without clear reasons, which renders results less clearly applicable to all patients. A more logical approach would be to study safety in a broad population and modify criteria as knowledge emerges.
Beaver et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: